Development and design of the BELpREG registration system for the collection of real-world data on medication use in pregnancy and mother-infant outcomes

- 1 Laure Sillis 1,2, Veerle Foulon 1, Karel Allegaert 1,3,4,5, Annick Bogaerts 3,4,6, Maarten De Vos 3,7,
- 2 Titia Hompes 8,9, Anne Smits 3,4,10, Kristel Van Calsteren 3,11, Jan Y Verbakel 12,13 and Michael
- 3 **Ceulemans** 1,4,14*

- ⁴ Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU
- 5 Leuven, Leuven, Belgium
- 6 ²Research Foundation Flanders (FWO), Brussels, Belgium
- 7 ³Department of Development and Regeneration, KU Leuven, Leuven, Belgium
- 8 ⁴L-C&Y, Child and Youth Institute, KU Leuven, Leuven, Belgium
- 9 ⁵Department of Clinical Pharmacy, Erasmus MC, Rotterdam, The Netherlands
- 10 ⁶Faculty of Health, University of Plymouth, Devon, UK
- ⁷Department of Electrical Engineering (ESAT), KU Leuven, Leuven, Belgium
- 12 ⁸Adult Psychiatry UPC, KU Leuven, Leuven, Belgium
- 13 ⁹Department of Neurosciences, KU Leuven, Leuven, Belgium
- 14 ¹⁰Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium
- 15 ¹¹Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
- 16 ¹²Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
- 17 ¹³Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 18 ¹⁴Teratology Information Service, Pharmacovigilance Centre Lareb, 's Hertogenbosch, the Netherlands
- * Correspondence: Michael Ceulemans (<u>michael.ceulemans@kuleuven.be</u>)
- 20 Keywords: pregnancy: drug information: drug safety: pharmacovigilance:
- 21 pharmacoepidemiology; registry; observational research; Belgium.

Abstract

23

40

- 24 Although medication use during pregnancy is common, most available products lack sufficient safety
- 25 information. As prospective data collection and perinatal pharmacoepidemiologic research on
- 26 medication safety in pregnancy did not exist in Belgium yet, the BELpREG data registration system
- was developed. BELpREG enables comprehensive 'real-world' data collection on perinatal
- 28 medication use and mother-infant outcomes via online questionnaires that are completed by pregnant
- women every four weeks during pregnancy and in the first eight weeks after childbirth. This paper
- describes the development and current design of the BELpREG system, including the list of
- 31 BELpREG variables. To compile this list of variables, relevant documents were explored, followed
- 32 by consultation of an interdisciplinary expert panel. The included variables were structured in seven
- categories: 1) Sociodemographic characteristics; 2) Information on the current pregnancy and health
- status; 3) Maternal-obstetric history; 4) Use of medicines, folic acid / pregnancy vitamins and other
- health products; 5) Substance use; 6) Pregnancy outcomes; and 7) Neonatal outcomes. An electronic
- 36 informed consent and linkage to medication databases, with images of drug packages and underlying
- 37 structured data fields, are built into the system. Data collection has officially started in November
- 38 2022. Based on its rigorous design, BELpREG holds the potential to be a successful and sustainable
- research tool, enabling perinatal pharmacoepidemiologic research in Belgium and beyond.

1 Introduction

- The use of medicines and health products in pregnancy occurs frequently (Lupattelli et al., 2014;
- 42 Gerbier et al., 2021; Ceulemans et al., 2022a; Gerbier et al., 2022). In Belgium, almost 90% of the
- women use at least one medicine in pregnancy, excluding pregnancy vitamins (Larcin et al., 2021).
- Safe use of medication in pregnancy is vital as the exposure to certain medicines may result in
- 45 adverse pregnancy, neonatal and/or infant outcomes. To date, there is a high need for reliable safety
- information on perinatal medication use, also in Belgium (Ceulemans et al., 2020; Ceulemans et al.,
- 47 2022b). The Internet, including social media, is a commonly used source to search for safety
- 48 information (Sinclair et al., 2018), however, discrepancies have been found between online sources
- 49 (Nörby et al., 2021). Furthermore, social media posts often provide inaccurate information, affecting
- women's perception and decisions about medication use (van Gelder et al., 2019).
- Despite their frequent use, most available medicines lack sufficient safety information on their use
- during pregnancy (Adam et al., 2011). On average, 27 years are needed to assign a precise risk
- 53 category to a medicine (Adam et al., 2011), and research to gain more information on the safe use of
- 54 medicines in pregnancy is challenging. Pregnant women are commonly excluded from clinical trials
- assessing the efficacy and safety of new medicinal products (Shields and Lyerly, 2013; Scaffidi et al.,
- 2017; Zhao et al., 2022). As soon as a product is on the market, marketing authorisation holders
- 57 (MAHs) are involved in the continuous monitoring of medication safety in pregnancy via post-
- 58 marketing surveillance, including spontaneous reporting and (mandatory) product-specific pregnancy
- registries. Still, a recent pan-European qualitative analysis performed by our team highlighted the
- difficulties with respect to data collection on this topic MAHs suffer from, including underreporting,
- 61 the collection of incomplete information, and loss to follow-up (Sillis et al., 2022). A recent
- 62 landscape analysis also confirmed that only few post-marketing studies result in label updates (Roque
- 63 Pereira et al., 2022).
- 64 In addition to post-marketing surveillance, other data sources could be used to gain insight into
- 65 medication safety during pregnancy, as for example: population-based cohorts nested in health
- utilisation databases (i.e., secondary use of health data) (Dandjinou et al., 2019; Huybrechts et al.,

- 67 2021; Moseholm et al., 2022), pregnancy registries held by non-MAHs (with or without a specific
- 68 focus on a pharmacotherapeutic class or therapeutic indication) (Hernandez-Diaz et al., 2012;
- 69 Chambers et al., 2019; Vorstenbosch et al., 2019), and data collection by Teratology Information
- Services (Pauliat et al., 2021; Dao et al., 2022). Different data sources come with different strengths,
- 71 limitations, and methodological considerations (Hernandez-Diaz and Oberg, 2015; Huybrechts et al.,
- 72 2019; Panchaud et al., 2022). In 2019, the Innovative Medicines Initiative (IMI) project
- 73 ConcePTION was launched to create a sustainable ecosystem to generate and disseminate
- 74 information on medication safety in pregnancy and during breastfeeding. This goal also includes the
- alignment of different organisations and approaches aimed at improving in the field of medication
- safety for pregnant and breastfeeding women (ConcePTION, n.d.).
- 77 Unfortunately, in Belgium, pharmacoepidemiologic research on medication safety in pregnancy is
- 78 lacking. The required data for such research are neither routinely collected, nor easily accessible,
- 79 compared to other European countries with comprehensive data on birth cohorts (e.g., Norway, the
- MoBa cohort) (Magnus et al., 2006) or with linked health utilisation databases (e.g., France,
- 81 EFEMERIS/POMME) (Lacroix et al., 2009; Benevent et al., 2019). This clearly highlights the need
- for comprehensive data registration in Belgium, and initiatives to expand this research field.
- 83 In 2021, our interdisciplinary consortium received KU Leuven funding to develop, validate and
- implement the BELpREG registration system in Belgium ("a **BEL**gian interdisciplinary initiative to
- 85 enhance pregnancy related data **REG**istration and research on medication use"). The BELpREG
- 86 registration system enables the collection of 'real-world', prospective, observational data on perinatal
- 87 medication use and mother-infant outcomes, by using online questionnaires to be completed by
- pregnant women. BELpREG is a non-disease, indication, pharmacotherapeutic class or product-
- 89 specific registry. In BELpREG, medication exposure and outcome data of all pregnant women (≥18
- 90 years and receiving health care in Belgium) are collected. The obtained data will be used for
- 91 pharmacoepidemiologic research in Belgium and beyond. On the long-term, BELpREG aims to
- ontribute to the provision of evidence on medication safety to expecting parents and HCPs. Figure 1
- shows a schematic overview of the BELpREG approach.
- In this paper, we describe the development and current design of the BELpREG registration system,
- 95 including the list of BELpREG variables, and future possibilities. Hence, this overview will inform
- 96 (inter)national researchers, MAHs, regulators and policy organizations involved in medication safety
- 97 monitoring in pregnancy about the BELpREG initiative, germinating opportunities for international
- 98 data pooling, analysis and collaborative projects.

Figure 1. A schematic overview of the BELpREG approach.



102

103

104

105

106

107

108

109

110

111 112

113

114

115

116 117

118119

120 121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

raised (September 2021).

2 **Materials and Methods** 2.1 Timing of the Development of BELpREG The development of the BELpREG data registration system on perinatal medication use and motherinfant outcomes occurred between March 2021 and October 2022. 2.2 **Development of the BELpREG Data Variables List** To compile the list of variables for data collection in BELpREG, relevant documents were explored, followed by a consultation of an interdisciplinary expert panel. First, the list of Core Data Elements (CDE), which was recently compiled as part of the IMI ConcePTION project (version December 2021, available via https://www.imiconception.eu/results/deliverables/) was consulted. The CDE had previously been defined based on in-depth discussions with experts in perinatal pharmacovigilance from in and outside the pharmaceutical industry, resulting in a set of essential variables required for pregnancy pharmacovigilance using prospective reports. The CDE aims to strengthen efficient collection of realworld data on medication safety in pregnancy (ConcePTION, n.d.). Second, the CDE were supplemented with variables defined in the European Medicines Agency (EMA) "Guideline on good pharmacovigilance practices (GVP) - Product- or Population-Specific Considerations III: Pregnant and breastfeeding women". This document provides guidance to MAHs and competent authorities with respect to data collection on pregnancy exposures and outcomes by listing questionnaire elements (see Appendix 1 of the GVP guideline, version December 2019, available via https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-goodpharmacovigilance-practices-product-population-specific-considerations-iii en.pdf). Finally, additional input regarding the variables and response options was sought in questionnaires of existing registration systems (i.e., Moeders van Morgen, The Netherlands; MotherToBaby, United States), and from the centre of expertise in Belgium on alcohol and substance use (i.e., Flemish Expertise Centre Alcohol and Other Drugs). These three approaches resulted in a preliminary set of variables, which was the starting point for the expert consultation. In a next step, an interdisciplinary expert panel was invited to contextualise the preliminary set of variables to the Belgian setting by providing input with regard, but not limited, to the definition of the variables, response options and formulations, and timing of the questions to be included in the BELpREG questionnaires. The panel consisted of seven Belgian experts in the field of obstetrics, neonatology/paediatrics (N = 2), midwifery, family medicine, perinatal psychiatry, and pharmacy, and were consulted in two rounds. In the first round, the experts completed an online survey (in Qualtrics; Augustus-September 2021) where they could indicate to which extent they agreed with any variables and/or response options; additional suggestions could be provided via open text fields. For each variable, experts were also asked to suggest the optimal timing and frequency of querying this variable. In the second round, the survey results were discussed in group during a real-life meeting, moderated by M.C. and L.S., to decide on inconsistent responses and/or any suggestions

2.3 Development of the BELpREG Infrastructure

- To develop the BELpREG registration system, including the technical infrastructure and legal,
- privacy and ethical framework for data collection and management, collaboration with external
- partners was set-up. Legal consultants with expertise in data protection and IP law in the field of life
- sciences were involved, as well as the Data Protection Officer of our institute, solving questions
- related to the collection of health data compliant with applicable privacy legislations, database
- protection and the use of the collected data for research purposes. Besides, IT consultants with
- extensive expertise in data systems related to medicines contributed to the construction of the
- BELpREG registration system and facilitated the longitudinal framework for data collection and
- linkage to existing databases (in collaboration with the IT department within our institute, KU
- 151 Leuven).

153

166

141

152 3 Results

3.1 BELpREG Data Categories and Variables

- Overall, BELpREG encompasses questions on data variables categorized in one of the following
- seven categories: 1) Sociodemographic characteristics; 2) Information on the current pregnancy and
- health status; 3) Maternal-obstetric history; 4) Use of medicines, folic acid / pregnancy vitamins and
- other health products; 5) Substance use; 6) Pregnancy outcomes; and 7) Neonatal outcomes (see
- Table 1). Information on these categories will be longitudinally collected using questionnaires at
- different time points during and after pregnancy. A detailed overview of the complete list of
- BELpREG variables, per category, can be found in the Supplementary Material 1. To optimally
- understand the remainder of this manuscript, some basic information about the categories is provided
- in the following paragraphs.
- 163 1) The category *Sociodemographic characteristics* consists of basic identifiers of BELpREG participants, as for example, zip code, nationality, ethnicity, or the socio-economic status of the
- mother and biological father (the latter only if known).
- 167 2) Information on the current pregnancy and health status will provide details on the estimated
- date of delivery (EDD), gestational age at completion of the pregnancy follow-up questionnaires,
- plurality, pregnancy preparation/planning/follow-up, current and previous health status of mother and
- biological father (e.g., comorbidities), and pregnancy complications diagnosed so far. Further, this
- category includes a screening of depressive symptoms during pregnancy and the postnatal period
- with the Edinburgh Depression Scale (EDS) (Cox et al., 1987; Bergink et al., 2011). The EDS is
- 173 considered the gold standard to detect PND (Cox et al., 1987). This scale was initially developed for
- the postpartum period but has also been validated for assessment during pregnancy (Bergink et al.,
- 175 2011). It consists of a 10-item list regarding the severity of the depressive symptoms during the past
- 176 7 days.

177

- 178 3) The category *Maternal-obstetric history* includes details on previous pregnancies, including
- miscarriages, elective terminations of pregnancy (ETOP), stillbirths, complications in previous
- pregnancies and familial predisposition to congenital anomalies, developmental disorders, and motor
- disorders.
- 183 4) The category *Use of medicines, folic acid / pregnancy vitamins and other health products* is
- divided into the use of medication, folic acid and/or pregnancy vitamins, and other health products,
- including details on administration route, amount of the exposure ('dose') and exact timing of

initiation and duration of exposure during pregnancy. Exposure to medicines and health products in the 6 months before the start of the current pregnancy is also questioned, along with paternal medication use in the 3 months before conception and maternal medication use in the first eight weeks postpartum.

- 5) The category *Substance use* includes variables questioning maternal exposure to alcohol, tobacco (i.e., smoking), cannabis, and other illicit substances. Besides, substance use in the proximity of the woman ('passive exposure') is covered as well, for example, by questioning about 'in-house' smoking by persons living together with the mother.
- 6) In the category *Pregnancy outcomes*, the addressed variables vary depending on the pregnancy outcome of the current pregnancy, i.e., the occurrence of a live birth, miscarriage, ectopic pregnancy, elective termination of pregnancy or stillbirth. In case of a live birth, additional questions about the delivery and potential postpartum complications are included.
- 7) The category *Neonatal outcomes* covers the health parameters of the infant, including the identification of congenital anomalies and the occurrence of neonatal complications, but also the feeding of the infant.

Table 1. Overview of the overarching BELpREG categories and variables, according to their occurrence in one of the four types of survey instruments

BELpREG categories and variables	Pregnancy Enrolment	Pregnancy Follow-up	First Postpartum	Second Postpartum
	Ouestionnaire	Ouestionnaire	Ouestionnaire	Ouestionnaire
Category 1: Sociodemographics	X	Questionnaire	Questionnaire	Questionnane
Category 2: Information on the current pregnancy and health status				
Pregnancy status		X		
EDD ¹ and/or current gestational age	x	x		
Singleton / multiple pregnancy	x			
Pregnancy preparation and planning	x			
Health status pregnant woman	X			
Health status and biological father (if applicable)	x			
Pregnancy complications and hospital admissions	x	X	X	
Prenatal screening for congenital anomalies				
Edinburgh Depression Scale (EDS-10)	x			X
Category 3: Maternal-obstetric history				
Gravidity and Parity	x			
History of miscarriages, ETOPs ² and stillbirths	x			
History of fertility treatments	x			
Complication(s) previous pregnancy/pregnancies	x			
Familial congenital anomalies	x			
Familial developmental disorders	x			
Familial motor disorders	x			
Category 4: Use of medicines, folic acid / pregnancy vitamins and				
other health products				
Medication use during pregnancy	x	X	X	
Use of folic acid or pregnancy vitamins prior to / in pregnancy	x	x	x	

Health products use during pregnancy	X	X	X	
Use of medicines and other health products in the	x			
6 months before conception				
Paternal medication use in the 3 months before conception	X			
Maternal medication use in the 8 weeks after delivery			X	X
Category 5: Substance use				
Maternal smoking	X	x	X	X
Maternal alcohol use	X	X	X	X
Cannabis and other illicit drug use by the woman	X	x	X	X
Substance use in the proximity of the woman	X			
Category 6: Pregnancy outcomes			X	
Outcomes in case of 'live born child'				
Single or multiple birth			X	
Delivery (e.g., onset of labor, type of delivery)			X	
Postpartum complications			X	x
Outcomes if miscarriage, ectopic pregnancy, ETOP ² or stillbirth			X	
Category 7: Neonatal outcomes				
Biometry at birth			X	X
(e.g., weight, length, head circumference)				
Sex			X	
Apgar score			X	
Congenital anomalies			X	х
Neonatal Abstinence symptoms			X	X
Neonatal medium or intensive care admission			X	x
Breastfeeding of the infant (e.g., breastfeeding, formula,)			X	X
Neonatal complications			X	X
Medication use by the infant			X	X

3.2 Longitudinal Framework for Data Collection

- 208 Determining the interval of successive questionnaires and the timing and frequency of addressing
- specific variables were key elements in the design of the BELpREG longitudinal framework.
- Following careful consideration, an interval of 4 weeks between two successive questionnaires was
- 211 chosen, with data collection until 8 weeks postpartum, except in case of consent withdrawal or early
- 212 pregnancy interruption.

- Four different survey instruments, each with specific data variables, were constructed: i.e., A) the
- 214 Pregnancy Enrolment Questionnaire; B) the Pregnancy Follow-up Questionnaire; C) the First
- 215 Postpartum Questionnaire; and D) the Second Postpartum Questionnaire. Table 1 gives an overview
- of the categories and variables questioned in each of the different questionnaires.
- Figure 2 provides a general overview of the BELpREG longitudinal framework, i.e., from enrolment
- 218 to study execution and termination of participation. More practical details about the framework are
- 219 provided in the following paragraph.

Figure 2. Overview of the BELpREG longitudinal framework, from enrolment to study execution

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246


247

248

249

250

251



To start data-collection, self-enrolment by pregnant persons is required, by using the link on the BELpREG website (www.belpreg.be) or scanning the QR code on BELpREG flyers. Enrolment is possible at any time during pregnancy, but participants will be encouraged to start as soon as possible in pregnancy. Once a pregnant person has enrolled, a new record ID is automatically generated in the BELpREG database, allowing longitudinal data collection on individual level. Upon completion of the digital consent procedure (see 3.3.1) and appropriateness check of the eligibility criteria (i.e., being pregnant, ≥18 years and receiving healthcare in Belgium), the Pregnancy Enrolment Questionnaire immediately starts. This is the most comprehensive questionnaire to be completed. It may take 20-30 minutes or even more, depending on gestational age at enrolment, gravidity and the number of medicines used during the current pregnancy so far. Completion of the Sociodemographic characteristics in the Pregnancy Enrolment Questionnaire triggers the scheduling of the subsequent e-mail invitations for the Pregnancy Follow-up Questionnaires. These Pregnancy Follow-up Ouestionnaires are generally expected to require less time to be completed, i.e., \pm 5-10 minutes, depending on the number of medicines, vitamins and health products used. The Pregnancy Follow-up Questionnaires mainly focus on medication and health products' use since the latest completed questionnaire (i.e., ideally, four weeks before), but also contain questions on pregnancy complications and maternal substance use (see Table 1 1). If a Pregnancy Follow-up Questionnaire is not completed after two weeks, a reminder is automatically sent via e-mail. The invitations for subsequent Pregnancy Follow-up Questionnaires are sent out, irrespective of whether the previous questionnaire(s) were completed, but with a maximum of 10 invitations per person. Once a participant indicates that the pregnancy has ended, the First Postpartum Questionnaire immediately appears. In case a miscarriage, stillbirth, ectopic pregnancy, or pregnancy termination is registered, participants do not receive additional questionnaires for this pregnancy anymore. They can register themselves again in the event of a new pregnancy. Only if a live birth is registered in the First Postpartum Questionnaire, the Second Postpartum Questionnaire is sent out four weeks later. In case of a live born twins, the questions related to Neonatal outcomes are automatically duplicated in both Postpartum Questionnaires. A Second Postpartum Questionnaire is only sent out if the First Postpartum Questionnaire was completed in the first 28 days after birth.

other health products have a longitudinal 'memory function'. This means that, if daily used

medicines or health products were registered, the names of these products as well as details related to

- 253 its use are automatically shown in the next questionnaire(s). This functionality gives participants the
- 254 opportunity to quickly and easily indicate if they still use the product in a similar way or not, and
- 255 hence, to save time because of this easy registration.

Infrastructure of the BELpREG Registration System

- The BELpREG registration system was built using Research Electronic Data Capture (REDCap) 257
- 258 software (Harris et al., 2009; Harris et al., 2019; Van Bulck et al., 2022). REDCap is a secure, web-
- 259 based, software platform, used to collect, manage, and store longitudinal research data. The
- 260 BELpREG REDCap system, database and back-up system are hosted on an institutional server
- 261 separated from other institutional REDCap projects, providing an additional layer of security. The
- 262 BELpREG REDCap system adheres to high-level data security standards and requires a multi-factor
- 263 authentication procedure for investigators to get access. Only pre-authorized users with fixed roles
- 264 (users rights) have access to the BELpREG REDCap management tool and database. Access to
- 265 REDCap records is automatically logged, and changes to recorded data are stored in *independent*
- 266 audit trails. In BELpREG, REDCap's security measures for identifiable data apply, i.e., identifier
- 267 tags are attached to variables collecting identifiers, ensuring that only pseudonymized data will be
- 268 extracted out of the database.

256

274

- 269 To fit the REDCap software to the specific needs of the BELpREG project, the following features
- 270 have been created: 1) digital consent procedure (eConsent) (see 3.3.1), 2) linkage of BELpREG
- 271 survey instruments with databases of medications and health products (see 3.3.2); and 3) linkage of
- 272 BELPREG survey instruments with external databases (see 3.3.3), to facilitate both data entry,
- 273 coding, and analysis, and to enhance user satisfaction.

3.3.1 eConsent Procedure

- 275 As personal and health data are processed in the BELpREG project, the General Data Protection
- 276 Regulation (GDPR) applies for each processing activity. Given the sensitive nature of the collected
- 277 data, along with our ambitions with respect to data pooling as part of (international) collaborative
- 278 projects, obtaining informed consent from participants prior to enrolment was necessary. However,
- 279 as pregnant persons should be able to enrol without physical/in-person contact with the BELpREG
- 280 researchers, the availability of a digital, 'remote' consent ('eConsent') was vital. Besides, according
- 281 to applicable legislation in Belgium on research involving human subjects, authentication of
- 282 participants was needed as part of the BELpREG consent procedure and required a simple solution.
- 283 The following eConsent procedure was developed using REDCap software and is currently in place
- 284 (see Supplementary Material 2). First, potential participants watch an instructive video, available on
- 285 the BELpREG website (www.belpreg.be), providing information on the objectives and course of the
- 286 project, inclusion criteria, risks and benefits, consent withdrawal and confidential treatment of the
- 287 collected data; this replaces the 'in-person' provision of study information as part of a regular
- 288 informed consent process. In case of questions, the researchers can easily be contacted via the
- 289 website, email, or phone. After watching the video, participants are redirected to the REDCap
- 290 environment. Once individuals confirm that they watched the video and want to sign the consent
- 291 form, an automatic e-mail is sent out containing a One-Time-Password (OTP), which should be used,
- 292 as authentication procedure, to sign the form 'remotely'. Once it is completed, a copy of the form is
- 293 stored by the researchers and sent to the participant, who can immediately start with the Pregnancy
- 294 Enrolment Questionnaire. This eConsent procedure, and the overall BELpREG research project, have
- 295 been approved by the local Ethics Committee Research UZ/KU Leuven (S66464).

3.3.2 Linked Databases of Medicines and Health Products

- 297 The survey instrument on *Use of medicines, folic acid / pregnancy vitamins and other health*
- 298 products includes linkages with both the official Belgian medication database (i.e., "Source
- 299 Authentique des Médicaments" or SAM) and the Medipim database (i.e., a database containing
- recent pictures of the packages of commercially available medicines and health products in Belgium).
- When participants enter the name of a medicine, vitamin, or other health product in a BELpREG
- questionnaire field, a structured and relevant dropdown list (based on both databases) appears that
- facilitates the selection of the right product. The linked databases allow data collection on
- medication, vitamin, and health products' use in a structured, reliable, and user-friendly way. At the
- same time, by using underlying structured data fields, the technical details of the registered medicines
- and products, such as, for example, the Anatomical Therapeutic Chemical classification (ATC) code
- and the route of administration, are automatically extracted from the linked databases and imported
- into the BELpREG database.

296

309

325

3.3.3 Other Linked Databases

- In addition to the structured data entry of medicines, vitamins, and health products, other BELpREG
- 311 variables also have underlying databases generating structured dropdown lists in their response field.
- This is the case for the registration of 1) country of residence and nationality (i.e., linked to the
- NATO database); 2) city of residence (i.e., linked to the database of the national post service in
- Belgium); 3) name of the hospital where the delivery took place (i.e., linked to the database of the
- National Institute for Health and Disability Insurance); and 4) the names of individual HCPs
- following-up BELpREG participants during pregnancy and in the postpartum period (i.e., also linked
- 317 to a database of the latter national institute). Furthermore, to register (chronic) disorders or
- indications of medications, participants can choose from a list of frequently reported
- indications/disorders. This list was developed based on literature and clinical experience with
- pregnant women and will grow over time (with up to five updates per year) based on experiences
- obtained by the registrations of BELpREG participants using this list. In the back-end of the system,
- 322 the indications/disorders are linked to their respective ICD-11 (International Classification of
- 323 Diseases 11th Revision, n.d.) and MedDRA code (Medical Dictionary for Regulatory Activities,
- 324 n.d.), facilitating data processing, analysis, and reporting, and data pooling.

4 Discussion

326

327

339

364

4.1 Development and Design of the BELpREG Registration System

- In this paper, we described the development and design of the BELpREG registration system,
- enabling the prospective collection of 'real-world', observational data on perinatal medication use
- and mother-infant outcomes in Belgium. After almost two years of constructing the system, we
- 331 succeeded in delivering the BELpREG infrastructure, including data variables, longitudinal
- framework, digital consent and linkage with medication and other databases. Given the current lack
- of routine data collection and pharmacoepidemiologic research on perinatal medication use in
- Belgium, BELpREG can be considered a unique registration system/initiative that merits attention
- from researchers, MAHs and policy makers in Belgium and beyond.
- In the next paragraphs, we will discuss in detail the value of the BELpREG variables (see 4.1.1),
- longitudinal framework and infrastructure (see 4.1.2) and recruitment of pregnant persons (see 4.1.3)
- and will elaborate on potential strengths and limitations of the system.

4.1.1 The BELpREG Variables

- 340 The current tools used for the registration of medication exposure in pregnancy and mother-infant
- outcomes, as part of international research initiatives on perinatal medication safety, often differ in
- 342 terms of exposure and outcome variables, including clinical definitions and coding standards (Thurin
- et al., 2022). Such registration variety clearly complicates data pooling across countries, necessitating
- additional standardization and alignment procedures with the inherent risk of considerable loss of
- data and/or granularity. Data pooling is, however, very important in this field to enlarge the sample
- size and power to detect significant associations, especially when studying rare outcomes such as
- 347 (specific types of) congenital malformations (Gelperin et al., 2017).
- Relying on relevant documents on medication safety in pregnancy research, such as the IMI
- 349 ConcePTION Core Data Elements (ConcePTION, n.d.), we pursued and eventually delivered a list of
- variables that are in line with those applied in other international data collection initiatives,
- 351 facilitating data pooling in the future. Contextualization to the Belgian setting was, however,
- considered appropriate, to maximize the feasibility and likelihood of obtaining complete and reliable
- data for all variables and to ensure user involvement and satisfaction. Contextualization was done
- with input from an interdisciplinary panel consisting of experts from the main professions involved in
- perinatal care. Despite the large number of variables, which may be cumbersome for participants, the
- integration of a broad set of potential confounders for associations between medication use and
- pregnancy outcomes is a strength of the BELpREG system. In fact, observational studies using health
- 358 utilisation data typically lack information on many confounders, entailing limitations in terms of the
- validity of the conclusions (Huybrechts et al., 2019; Panchaud et al., 2022). With respect to the
- 360 feeding status of the infant, breastfeeding or receiving breast milk will be asked, which is considered
- an important but often ignored source of medication exposure, a mitigator of adverse effects or a
- relevant covariate in pharmacoepidemiologic research on the long-term effects of medication use in
- pregnancy (Jordan et al., 2022).

4.1.2 The BELpREG Longitudinal Framework and Technical Infrastructure

- As the ambition is to use BELpREG data for longitudinal research, the BELpREG system needed to
- 366 consist of online questionnaires which are sent and (ideally) completed by pregnant persons at
- multiple time points during and after pregnancy. We opted for a fixed interval of four weeks, lasting
- 368 at least for now until eight weeks postpartum. By choosing this time interval, we tried to find the

- right balance between registration fatigue among participants and recall bias for the self-reported
- 370 registration of medication and/or health products used in the previous period (van Gelder et al.,
- 371 2018). Upon enrolment, BELpREG participants are prospectively followed-up, i.e., they register
- exposure data throughout pregnancy without knowing the pregnancy outcome yet. Collecting data in
- a prospective way is an important strength in observational research, potentially decreasing the risk
- of bias (Schaefer et al., 2008). Yet, in the Pregnancy Enrolment Questionnaire, we ask what
- medicines/health products were used from the start of pregnancy until then. In case of late enrolment
- during pregnancy (i.e., at more advanced gestational age), the risk of recall bias could be very
- 377 relevant. In any case, in all our communication, we advise and encourage individuals to enrol as early
- as possible during pregnancy, although enrolment is possible at any gestational age.
- 379 To support participants in registering their medicines and health products, a linkage with databases of
- medicines and health products available in Belgium was built, including pictures of the drug
- packages (see 3.3.2). At user level, these linkages may improve the user friendliness of the system
- 382 (i.e., by facilitating the registration of their products from a dropdown list). At system level, the
- 383 linkages with medication and other types of databases, for example related to nationality or zip-code,
- may have positive effects in terms of correctness/quality of the collected data (i.e., by
- selecting/recognizing the correct product by means of its picture) and ease of further data processing
- 386 (i.e., by automatically importing relevant parameters, such as ATC code, in the BELpREG database).
- The retained variables, linked databases and longitudinal framework were built into REDCap
- software, which is an internationally recognized research tool for data collection and management
- 389 (Harris et al., 2009; Harris et al., 2019; Van Bulck et al., 2022), facilitating data collection initiatives
- in other settings or countries in the future by relying on the BELpREG infrastructure.
- When defining the BELpREG design, the perspectives of MAHs towards medication safety
- monitoring and pharmacovigilance during pregnancy have been considered (Sillis et al., 2022),
- thereby maximizing the added value of BELpREG for MAHs and facilitating future collaborations
- by means of contract research with, for example, the aim to update the pregnancy statements in the
- 395 product labels (Roque Pereira et al., 2022).
- Nevertheless, when using the BELpREG data for descriptive/analytical pharmacoepidemiologic
- purposes, it should be noted that the reliability of the conclusions depends on the quality of the self-
- 398 reported data. Hence, assessing the correctness of the collected data by means of a validation study is
- warranted and has already been initiated (see 4.2).

4.1.3 Recruitment of Pregnant Individuals

- The success of 'citizen science' initiatives such as BELpREG depends on the level of involvement by
- pregnant participants. Likewise, its success also lies in collaborating with other data collection
- 403 initiatives abroad, especially as Belgium is a small country with 'only' 120 000 pregnant women per
- 404 year (Statbel, 2023). Therefore, difficulties can be expected to obtain enough exposed women, solely
- based on data collection in our country, to draw firm conclusions on associations. Data pooling will
- be key, also for timely signal detection. Nevertheless, capturing every single piece of data is ethically
- appropriate and must be pursued.

- 408 To reach pregnant persons, also those who are not using (chronic) medicines, applying diverse
- recruitment methods is vital (Goldstein et al., 2021). Therefore, to date, pregnant persons are
- 410 informed about BELpREG both in-person (direct, by HCPs) and online (indirect). First, details about
- 411 BELpREG are being shared with different types of HCPs involved in perinatal care (i.e.,

- 412 obstetricians, midwives, general practitioners, pharmacists...), with support from their professional
- 413 organizations and regional care organizations. The embeddedness of BELpREG in the local
- 414 healthcare context for pregnant persons may be a critical aspect for its successful uptake by potential
- 415 users (Sillis et al., 2022). Sustainable partnerships between the research team and HCPs, prenatal care
- 416 organizations and hospitals has earlier been shown as a core strategy for successful recruitment
- 417 (Goldstein et al., 2021), and are currently being set-up in within BELpREG. Second, indirect
- 418 recruitment strategies are being used by means of our website, social media (Facebook, Instagram),
- 419 and printed/digital posters and flyers. As poor public awareness of research among different groups
- 420 within the population is a large barrier for participation in research (Goldstein et al., 2021), social
- 421 media can be an effective method to reach a broader audience, independent from efforts by HCPs. In
- 422 fact, the population of pregnant women often uses social media to search for information (Sinclair et
- 423 al., 2018). In addition, high internet penetration rates exist among women of childbearing age in
- 424 Belgium (Statbel, 2022). Previous research has shown the advantages of recruiting pregnant women
- 425 through social media, including advertisement via these channels (van Gelder et al., 2019). Although
- 426 social media seem a logical recruitment channel for BELpREG, its effectiveness should be further
- 427 explored, including the effect of directly approaching the target population via (advertising using)
- 428 social media (Sarker et al., 2017).
- 429 As study enrolment in BELpREG occurs without physical contact with the researchers, the ability to
- 430 provide remote informed consent is paramount. Therefore, in BELpREG, a user-friendly and GDPR
- 431 compliant eConsent framework was specifically developed according to the applicable legislation in
- 432 Belgium (see 3.3.1). The use of an eConsent in REDCap has previously been shown to be feasible
- 433 and easy-to-use by pregnant women (Phillippi et al., 2018). In the future, the BELpREG eConsent
- 434 framework could serve as an instrument or starting point for similar research purposes in other
- 435 populations and/or settings.

Future Perspectives of BELpREG

- 437 As part of the development stage, the BELpREG infrastructure was extensively tested 'in-house' on
- 438 functionality and technical performance by different persons and by using different scenarios. In
- 439 November 2022, public data collection has officially started. However, as the next step, we have
- 440 planned to closely follow-up and explore the ongoing data collection in 'real-life' and the preliminary
- 441 data. Such iterative process of testing, followed by possible system modifications, will result in a
- 442 robust, patient-friendly, and fit-for-purpose research instrument, ready for large-scale implementation
- 443 in Belgium and beyond. The assessment will focus on 1) the completeness of the collected data, both
- 444 within (i.e., missing variables) and across questionnaires (i.e., loss to follow-up); 2) the 'reach' or
- 445 representativeness of the BELpREG sample (as research using online questionnaires typically only
- 446 reaches a select group of the population (Vorstenbosch et al., 2019; van Gelder et al., 2020; Stegherr
- 447 et al., 2022)); 3) users' experiences and challenges with data entry (by means of a mixed-methods
- 448 approach); 4) experiences of HCPs with informing and motivating pregnant individuals to participate
- 449 in BELpREG.
- 450 In addition to the feasibility assessment, we will undertake a validation study to evaluate the quality
- 451 of the self-reported data. Patients may probably be best placed to record their medication use (van
- 452 Gelder et al., 2018), however, it remains unclear to what extent they are able to correctly register
- 453 pregnancy and neonatal outcomes (e.g., type and description of congenital anomalies). Therefore, the
- 454 validity of self-registered health data will be assessed by comparing with the data available in
- 455 medical/obstetric records (only for participants who gave consent to contact their HCPs). In case the
- 456 validation study shows that these variables can indeed be reliably registered by patients, this will

- 457 avoid an additional registration burden for HCPs. Overall, it should be further explored to what
- extent HCPs would be able to register data in BELpREG themselves, for example for patients with
- low health literacy or impaired internet access.
- 460 Another important future perspective relates to the exploration for long-term follow-up of children
- born after prenatal exposure to medicines. To date, the BELpREG design only includes maximum
- 462 two questionnaires in the first eight weeks postpartum, addressing neonatal health outcomes.
- However, some exposures may result in adverse neurodevelopmental outcomes in offspring, which
- only become visible months or years after birth (Liu et al., 2017; Bromley and Bluett-Duncan, 2021).
- We have the ambition to extend our postpartum questionnaires for long-term follow-up purposes, and
- 466 therefore look expectantly at the ongoing LIFETIME project (i.e., Long-term Investigation Following
- Exposure To Individual Medicines in utEro) (ConcePTION, n.d.). As a first step, BELpREG
- participants are being asked about their willingness to complete self-reported surveys at the age of
- developmental milestones (Hjorth et al., 2019).
- 470 Finally, translating the BELpREG questionnaires into other (national) languages (e.g., French,
- English) is also an intended goal, which we hope to achieve in the (near) future.

472 **5 Conclusions**

- 473 Due to the current lack of routine data collection and pharmacoepidemiologic research on medication
- safety in pregnancy in Belgium, the BELpREG registration system was developed. As a 'citizen
- science' project, the BELpREG system enables the prospective and longitudinal collection of
- 476 comprehensive, real-world data on perinatal medication use and mother-infant outcomes. Online
- 477 questionnaires will be completed by pregnant persons every four weeks during pregnancy and in the
- 478 first eight weeks postpartum.
- The variables were compiled using relevant documents and through an expert panel consultation and
- are structured in seven categories. A digital, 'remote' informed consent and linkage to medication
- databases, with images of drug packages and underlying structured data fields, are built into the
- system, which uses REDCap as software. Data collection has officially started in November 2022.
- Based on its rigorous and fully digital design, BELpREG holds the potential to be a successful,
- sustainable, and collaborative research tool, enabling perinatal pharmacoepidemiologic research in
- Belgium and beyond. Researchers, MAHs and policy makers are invited to contact the researchers to
- 486 explore future collaborations and data pooling, with the aim to reduce the current knowledge gap in
- 487 this field and to provide more evidence on medication safety in pregnancy to patients and HCPs.

6 Conflict of Interest

- 489 The authors declare that the research was conducted in the absence of any commercial or financial
- 490 relationships that could be construed as a potential conflict of interest.

7 Supplementary Material

- The following supporting information can be downloaded: Supplementary Table1: Detailed overview
- of the BELpREG variables, per category; Supplementary Figure 2: Schematic overview of the
- 494 eConsent procedure.

488

491

8 Author Contributions

- 497 Conceptualization, L.S., V.F. and M.C.; methodology, L.S., V.F., K.A., A.B., M.D.V., T.H., A.S.,
- 498 K.V.C., J.Y.V. and M.C.; software, L.S. and M.C.; validation, L.S., V.F. and M.C.; formal analysis,
- 499 L.S. and M.C.; investigation, L.S. and M.C.; resources, V.F., M.C. and L.S.; data curation, L.S.;
- writing-original draft preparation, L.S. and M.C.; writing-review and editing, V.F., K.A., A.B.,
- M.D.V., T.H., A.S., K.V.C., and J.Y.V.; supervision, V.F. and M.C.; project administration, L.S. and
- M.C.; funding acquisition, V.F., M.C. and L.S.. All authors have read and agreed to the published
- version of the manuscript.

504 **9 Funding**

- 505 The development of BELpREG was funded by a KU Leuven internal fund (C3/020/095). The
- research activities of Laure Sillis are funded by the Research Foundation Flanders (FWO)
- 507 (1S35823N). The research activities of Michael Ceulemans are supported by the Department of
- 508 Pharmaceutical and Pharmacological Sciences and the Faculty of Pharmaceutical Sciences of the KU
- 509 Leuven.

496

510 **10** Acknowledgments

- The authors would like to thank the following persons for their input and help through the
- development of BELpREG: Hilde De Tollenaere and Peter Van Rompaey (Clinical Trial Center,
- 513 University Hospitals Leuven), Eugène Van Puijenbroek (Lareb, NL), Saskia Vorstenbosch (NL),
- Carlijn Litjens (NL), Ellen Ederveen (Lareb, NL), Judith Hendriks (Lareb, NL), Jonathan Luke
- Richardson (UKTIS, UK), Rebecca Bromley and Matthew Bluett-Duncan (University of Manchester,
- 516 UK), Liesbet Van Bulck (KU Leuven), Alexis Puvrez (KU Leuven) and Gert Goos (ICT Service, KU
- Leuven). The authors are also grateful to the BELpREG partners Digile (IT support An Crepel,
- Karel De Loof and Davy Hollevoet), Medipim (providing pictures of medicinal products),
- Allen&Overy (legal advice) and Isabelle Geeraerts (graphical design). Finally, the authors thank all
- 520 colleagues and women who have contributed to the in-house testing of the system.

521 **12 Data Availability Statement**

Not applicable.

523

11 Note from the authors

- The list of used REDCap features is not exhaustive. The mentioned features of REDCap used in the
- 525 BELpREG project are a choice of the authors. Complete information about REDCap features can be
- found here: https://projectredcap.org/.

527 **12 References**

- 528 Adam, M.P., Polifka, J.E., and Friedman, J.M. (2011). Evolving knowledge of the teratogenicity of
- medications in human pregnancy. American Journal of Medical Genetics Part C: Seminars in
- 530 *Medical Genetics* 157(3), 175-182. doi: 10.1002/ajmg.c.30313.
- Benevent, J., Hurault-Delarue, C., Araujo, M., Montastruc, J.L., Lacroix, I., and Damase-Michel, C.
- 532 (2019). POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine
- 533 Exposure. *Drug Saf* 42(1), 45-54. doi: 10.1007/s40264-018-0712-9.

- Bergink, V., Kooistra, L., Lambregtse-van den Berg, M.P., Wijnen, H., Bunevicius, R., van Baar, A., et al. (2011). Validation of the Edinburgh Depression Scale during pregnancy. *J Psychosom Res* 70(4), 385-389. doi: 10.1016/j.jpsychores.2010.07.008.
- Bromley, R.L., and Bluett-Duncan, M. (2021). Neurodevelopment Following Exposure to Antiseizure Medications in Utero: A Review. *Curr Neuropharmacol* 19(11), 1825-1834. doi: 10.2174/1570159x19666210716111814.

- Ceulemans, M., Fortuin, M., Van Calsteren, K., Allegaert, K., and Foulon, V. (2020). Prevalence and characteristics of pregnancy- and lactation-related calls to the National Poison Centre in Belgium: A retrospective analysis of calls from 2012 to 2017. *Journal of Evaluation in Clinical Practice* 26(3), 911-917. doi: 10.1111/jep.13228.
 - Ceulemans, M., Foulon, V., Panchaud, A., Winterfeld, U., Pomar, L., Lambelet, V., et al. (2022a). Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries. *International Journal of Environmental Research and Public Health* 19(3), 1389. doi: 10.3390/ijerph19031389.
 - Ceulemans, M., Van Calsteren, K., Allegaert, K., and Foulon, V. (2022b). Information Needs and Counseling Preferences among Potential Users of the Future Teratology Information Service in Belgium: A Cross-Sectional Study Involving the Public and Healthcare Professionals. *International Journal of Environmental Research and Public Health* 19(14), 8605. doi: 10.3390/ijerph19148605.
 - Chambers, C.D., Johnson, D.L., Xu, R., Luo, Y., Lopez-Jimenez, J., Adam, M.P., et al. (2019). Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. *PLOS ONE* 14(10), e0223603. doi: 10.1371/journal.pone.0223603.
 - ConcePTION. (n.d.). https://www.imi-conception.eu/ [Accessed February 14, 2023].
- Cox, J.L., Holden, J.M., and Sagovsky, R. (1987). Detection of Postnatal Depression. *British Journal of Psychiatry* 150(6), 782-786. doi: 10.1192/bjp.150.6.782.
 - Dandjinou, M., Sheehy, O., and Bérard, A. (2019). Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case—control study. *BMJ Open* 9(9), e025908. doi: 10.1136/bmjopen-2018-025908.
 - Dao, K., Shechtman, S., Diav-Citrin, O., George, N., Richardson, J.L., Rollason, V., et al. (2022). Reproductive Safety of Trazodone After Maternal Exposure in Early Pregnancy: A Comparative ENTIS Cohort Study. *Journal of Clinical Psychopharmacology*, 10.1097/JCP.00000000000001630. doi: 10.1097/jcp.0000000000001630.
 - EMA (2019). "GVP Product- or Population-Specific Considerations III: Pregnant and breastfeeding women (EMA/653036/2019) Draft for public consultation".).
 - Gelperin, K., Hammad, H., Leishear, K., Bird, S.T., Taylor, L., Hampp, C., et al. (2017). A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection. *Pharmacoepidemiology and Drug Safety* 26(2), 208-214. doi: 10.1002/pds.4150.
 - Gerbier, E., Favre, G., Tauqeer, F., Winterfeld, U., Stojanov, M., Oliver, A., et al. (2022). Self-Reported Medication Use among Pregnant and Postpartum Women during the Third Wave of the COVID-19 Pandemic: A European Multinational Cross-Sectional Study. *International Journal of Environmental Research and Public Health* 19(9), 5335. doi: 10.3390/ijerph19095335.
- Gerbier, E., Graber, S.M., Rauch, M., Marxer, C.A., Meier, C.R., Baud, D., et al. (2021). Use of drugs to treat symptoms and acute conditions during pregnancy in outpatient care in Switzerland between 2014 and 2018: analysis of Swiss healthcare claims data. *Swiss Med Wkly* 151, w30048. doi: 10.4414/smw.2021.w30048.
- Goldstein, E., Bakhireva, L.N., Nervik, K., Hagen, S., Turnquist, A., Zgierska, A.E., et al. (2021).
 Recruitment and retention of pregnant women in prospective birth cohort studies: A scoping

- review and content analysis of the literature. *Neurotoxicology and Teratology* 85, 106974. doi: https://doi.org/10.1016/j.ntt.2021.106974.
- Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O'Neal, L., et al. (2019). The REDCap consortium: Building an international community of software platform partners. *Journal of Biomedical Informatics* 95, 103208. doi: 10.1016/j.jbi.2019.103208.
- Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009). Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Informatics* 42(2), 377-381. doi: 10.1016/j.jbi.2008.08.010.

- Hernandez-Diaz, S., and Oberg, A.S. (2015). Are Epidemiological Approaches Suitable to Study Risk/Preventive Factors for Human Birth Defects? *Current Epidemiology Reports* 2(1), 31-36. doi: 10.1007/s40471-015-0037-5.
- Hernandez-Diaz, S., Smith, C.R., Shen, A., Mittendorf, R., Hauser, W.A., Yerby, M., et al. (2012). Comparative safety of antiepileptic drugs during pregnancy. *Neurology* 78(21), 1692-1699. doi: 10.1212/wnl.0b013e3182574f39.
- Hjorth, S., Bromley, R., Ystrom, E., Lupattelli, A., Spigset, O., and Nordeng, H. (2019). Use and validity of child neurodevelopment outcome measures in studies on prenatal exposure to psychotropic and analgesic medications A systematic review. *PLOS ONE* 14(7), e0219778. doi: 10.1371/journal.pone.0219778.
 - Huybrechts, K.F., Bateman, B.T., and Hernández-Díaz, S. (2019). Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy. *Pharmacoepidemiology and Drug Safety* 28(7), 906-922. doi: 10.1002/pds.4789.
 - Huybrechts, K.F., Bateman, B.T., Zhu, Y., Straub, L., Mogun, H., Kim, S.C., et al. (2021). Hydroxychloroquine early in pregnancy and risk of birth defects. *American Journal of Obstetrics and Gynecology* 224(3), 290.e291-290.e222. doi: 10.1016/j.ajog.2020.09.007.
- International Classification of Diseases 11th Revision (ICD-11). (n.d.). https://icd.who.int/en [Accessed February 14, 2023].
 - Jordan, S., Bromley, R., Damase-Michel, C., Given, J., Komninou, S., Loane, M., et al. (2022). Breastfeeding, pregnancy, medicines, neurodevelopment, and population databases: the information desert. *International Breastfeeding Journal* 17(1). doi: 10.1186/s13006-022-00494-5.
 - Lacroix, I., Hurault, C., Sarramon, M.F., Guitard, C., Berrebi, A., Grau, M., et al. (2009). Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. *European Journal of Clinical Pharmacology* 65(8), 839-846. doi: 10.1007/s00228-009-0647-2.
 - Larcin, L., Lona, M., Karakaya, G., Van Espen, A., Damase-Michel, C., and Kirakoya-Samadoulougou, F. (2021). Using administrative healthcare database records to study trends in reimbursed medication dispensed during pregnancy in Belgium from 2003 to 2017. *Pharmacoepidemiol Drug Saf.* doi: 10.1002/pds.5299.
- Liu, X., Agerbo, E., Ingstrup, K.G., Musliner, K., Meltzer-Brody, S., Bergink, V., et al. (2017).
 Antidepressant use during pregnancy and psychiatric disorders in offspring: Danish nationwide register based cohort study. *BMJ*, j3668. doi: 10.1136/bmj.j3668.
- Lupattelli, A., Spigset, O., Twigg, M.J., Zagorodnikova, K., Mårdby, A.C., Moretti, M.E., et al. (2014).
 Medication use in pregnancy: a cross-sectional, multinational web-based study. *BMJ Open*4(2), e004365. doi: 10.1136/bmjopen-2013-004365.
- Magnus, P., Irgens, L.M., Haug, K., Nystad, W., Skjærven, R., and Stoltenberg, C. (2006). Cohort profile: The Norwegian Mother and Child Cohort Study (MoBa). *International Journal of Epidemiology* 35(5), 1146-1150. doi: 10.1093/ije/dyl170.
- Medical Dictionary for Regulatory Activities (MedDRA). (n.d.). https://www.meddra.org/ [Accessed February 14, 2023].

- 632 Moseholm, E., Katzenstein, T.L., Pedersen, G., Johansen, I.S., Wienecke, L.S., Storgaard, M., et al. 633 (2022). Use of antiretroviral therapy in pregnancy and association with birth outcome among 634 women living with HIV in Denmark: A nationwide, population-based cohort study. HIV 635 Medicine 23(9), 1007-1018. doi: 10.1111/hiv.13304.
- Nörby, U., Noël-Cuppers, B., Hristoskova, S., Desai, M., Härmark, L., Steel, M., et al. (2021). Online 636 637 information discrepancies regarding safety of medicine use during pregnancy and lactation: an 638 IMI ConcePTION study. Expert Opinion on Drug Safety 20(9), 1117-1124. doi: 639 10.1080/14740338.2021.1935865.

641

643

644

645

646

647 648

649

650

651

652

653 654

655

656

657

658

659

660

661

662 663

664

665 666

667

668 669

670

671

- Panchaud, A., Cleary, B., Weber-Schoendorfer, C., Shechtman, S., Cassina, M., Diav-Citrin, O., et al. (2022). The risk of questioning the safety of drugs considered safe in pregnancy at the era of big data: the everlasting case of doxylamine. J Clin Epidemiol 152, 125-126. doi: 642 10.1016/j.jclinepi.2022.10.007.
 - Pauliat, E., Onken, M., Weber-Schoendorfer, C., Rousson, V., Addor, M.-C., Baud, D., et al. (2021). Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Multiple Sclerosis Journal 27(3), 475-478. doi: 10.1177/1352458520929628.
 - Phillippi, J.C., Doersam, J.K., Neal, J.L., and Roumie, C.L. (2018). Electronic Informed Consent to Facilitate Recruitment of Pregnant Women Into Research. Journal of Obstetric, Gynecologic & Neonatal Nursing 47(4), 529-534. doi: 10.1016/j.jogn.2018.04.134.
 - Roque Pereira, L., Durán, C.E., Layton, D., Poulentzas, G., Lalagkas, P.-N., Kontogiorgis, C., et al. (2022). A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project. Drug Safety 45(4), 333-344. doi: 10.1007/s40264-022-01154-7.
 - Sarker, A., Chandrashekar, P., Magge, A., Cai, H., Klein, A., and Gonzalez, G. (2017). Discovering Cohorts of Pregnant Women From Social Media for Safety Surveillance and Analysis. Journal of Medical Internet Research 19(10), e361. doi: 10.2196/jmir.8164.
 - Scaffidi, J., Mol, B., and Keelan, J. (2017). The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology 124(1), 132-140. doi: 10.1111/1471-0528.14151.
 - Schaefer, C., Ornoy, A., Clementi, M., Meister, R., and Weber-Schoendorfer, C. (2008). Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. *Reprod Toxicol* 26(1), 36-41. doi: 10.1016/j.reprotox.2008.05.064.
 - Shields, K.E., and Lyerly, A.D. (2013). Exclusion of pregnant women from industry-sponsored clinical trials. Obstet Gynecol 122(5), 1077-1081. doi: 10.1097/AOG.0b013e3182a9ca67.
 - Sillis, L., Foulon, V., Verbakel, J.Y., and Ceulemans, M. (2022). Experiences and Perspectives of Marketing Authorisation Holders towards Medication Safety Monitoring during Pregnancy: A Pan-European Qualitative Analysis. International Journal of Environmental Research and Public Health 19(7), 4248. doi: 10.3390/ijerph19074248.
 - Sinclair, M., Lagan, B.M., Dolk, H., and McCullough, J.E.M. (2018). An assessment of pregnant women's knowledge and use of the Internet for medication safety information and purchase. Journal of Advanced Nursing 74(1), 137-147. doi: 10.1111/jan.13387.
- 674 Statbel. (2022). ICT use in households in Belgium. https://statbel.fgov.be/nl/themas/huishoudens/ict-675 gebruik-huishoudens [Accessed February 14, 2023].
- Statbel. (2023). Births and Fertility in Belgium. https://statbel.fgov.be/nl/themas/bevolking/geboorten-676 677 en-vruchtbaarheid [Accessed February 14, 2023].
- 678 Stegherr, R., Beck, E., Hultzsch, S., Schaefer, C., and Dathe, K. (2022). Can non-responding mask or 679 mimic drug effects on pregnancy outcome? Evaluation of case characteristics based on the 680 national Embryotox cohort. Reproductive Toxicology. doi: 10.1016/j.reprotox.2022.05.013.

- Thurin, N.H., Pajouheshnia, R., Roberto, G., Dodd, C., Hyeraci, G., Bartolini, C., et al. (2022). From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. *Clinical Pharmacology & Therapeutics* 111(1), 321-331. doi: 10.1002/cpt.2476.
- Van Bulck, L., Wampers, M., and Moons, P. (2022). Research Electronic Data Capture (REDCap): tackling data collection, management, storage, and privacy challenges. *European Journal of Cardiovascular Nursing* 21(1), 85-91. doi: 10.1093/eurjcn/zvab104.

- van Gelder, M.M.H.J., Merkus, P.J.F.M., Van Drongelen, J., Swarts, J.W., Van De Belt, T.H., and Roeleveld, N. (2020). The PRIDE Study: Evaluation of online methods of data collection. *Paediatric and Perinatal Epidemiology* 34(5), 484-494. doi: 10.1111/ppe.12618.
- van Gelder, M.M.H.J., Rog, A., Bredie, S.J.H., Kievit, W., Nordeng, H., and Belt, T.H. (2019). Social media monitoring on the perceived safety of medication use during pregnancy: A case study from the Netherlands. *British Journal of Clinical Pharmacology* 85(11), 2580-2590. doi: 10.1111/bcp.14083.
- van Gelder, M.M.H.J., Van De Belt, T.H., Engelen, L.J.L.P.G., Hooijer, R., Bredie, S.J.H., and Roeleveld, N. (2019). Google AdWords and Facebook Ads for Recruitment of Pregnant Women into a Prospective Cohort Study With Long-Term Follow-Up. *Maternal and Child Health Journal* 23(10), 1285-1291. doi: 10.1007/s10995-019-02797-2.
- van Gelder, M.M.H.J., Vorstenbosch, S., Te Winkel, B., van Puijenbroek, E.P., and Roeleveld, N. (2018). Using Web-Based Questionnaires to Assess Medication Use During Pregnancy: A Validation Study in 2 Prospectively Enrolled Cohorts. *Am J Epidemiol* 187(2), 326-336. doi: 10.1093/aje/kwx239.
- Vorstenbosch, S., Te Winkel, B., van Gelder, M.M.H.J., Kant, A., Roeleveld, N., and van Puijenbroek, E. (2019). Aim and Design of pREGnant, the Dutch Pregnancy Drug Register. *Drug Saf* 42(1), 1-12. doi: 10.1007/s40264-018-0722-7.
- Zhao, Y., Du, G., Luan, X., Yang, H., Zhang, Q., Zhang, Z., et al. (2022). Registered Clinical Trials
 Comprising Pregnant Women in China: A Cross-Sectional Study. Frontiers in Pharmacology
 doi: 10.3389/fphar.2022.850080.